A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center.
The study – the first trial to publish five-year results from SBRT treatment for prostate cancer – found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target. It is a state-of-the-art technology that allows for a concentrated dose to reach the tumor while limiting the radiation dose to surrounding healthy tissue.
“The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,” said Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study. “What we now have is a more potent and effective form of completely noninvasive treatment for prostate cancer, conveniently completed in five treatments.”
Conventional treatment options for early stage prostate cancer include:
- Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;
- Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room. Once implanted, the seeds release their radioactivity directly into the prostate gland; and
- External beam radiation, which involves 42 to 45 treatments administered over two or more months, five days a week.
“The current form of radiation is 44 treatments given over nine weeks. In contrast, the SBRT therapy we used allows the delivery of highly focused radiation in only five treatments, allowing patients to return to their normal lives more quickly,” said senior author Dr. Robert Timmerman, Director of the Annette Simmons Stereotactic Treatment Center at UT Southwestern, and Professor and Vice Chairman of the Department of Radiation Oncology. “SBRT is both more convenient and has increased potency.”
UT Southwestern served as the lead site for the multi-institutional clinical trial, which involved first-time prostate cancer patients diagnosed with stage I or stage II (low and intermediate risk) prostate cancer. A total of 91 patients were treated prospectively and followed for five years, with only one patient experiencing a recurrence of his cancer. The findings are published in the European Journal of Cancer.
Terry Martin of McKinney, Texas, – about an hour outside Dallas – said the fewer number of treatments was a compelling advantage when he was evaluating treatment options.
“I live 45 minutes away from UT Southwestern. The difference between being treated five times versus 44 times is enormous,” said Mr. Martin, a retired airline pilot. “I felt that I was back to normal just 10 days after finishing treatment.”
In addition to shorter treatment times, researchers found that side effects were not necessarily different compared to other forms of prostate cancer treatment. In the short term, the side effects of SBRT can include urinary issues (urgency, frequency and burning) and rectal irritation, which are often temporary and reverse within four weeks of treatment. Researchers found a small risk of longer-term urinary and rectal complications, which is also comparable to conventional treatments. Decrease in erectile function was seen in 25 percent of patients, fewer than with conventional radiation or surgery, said Dr. Hannan.
Learn more: Research shows 98% cure rate for prostate cancer using Stereotactic Body Radiation Therapy
The Latest on: Stereotactic Body Radiation Therapy
[google_news title=”” keyword=”Stereotactic Body Radiation Therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Stereotactic Body Radiation Therapy
- Definitive Therapy to the Primary Site Improves Survival in Brain-Only Metastatic NSCLCon April 26, 2024 at 7:01 am
Definitive treatment to the primary site improves overall and cancer-specific survival among patients with brain-only NSCLC metastases, a recent retrospective study shows.
- WOO Network trials investigate innovative treatments for liver, head and neck cancerson April 20, 2024 at 10:44 pm
A new round of clinical trials supported by the Ontario Institute for Cancer Research (OICR) will harness a unique opportunity to test some of the newest treatment strategies for a range of different ...
- Managing head and neck cancer with the latest treatment modalitieson April 17, 2024 at 12:10 am
Alyssa's battle with tongue cancer underscores the importance of advanced treatments like immunotherapy and precision medicine. Her journey sheds light on the evolving landscape of cancer care, ...
- How To Treat Pineoblastomaon April 16, 2024 at 2:55 pm
Pineoblastoma is a type of cancer that starts in the pineal gland cells, which are located in the center of the brain.
- Adjuvant breast radiotherapy: KUH unlocks the clinical upsides of tangential VMATon April 16, 2024 at 6:15 am
Tangential VMAT (tVMAT) is the treatment modality of choice for adjuvant breast radiotherapy at Kuopio University Hospital in Finland ...
- KMC Hospital Attavar Oncology Centre Introduces Stereotactic Radiotherapy for Cancer Treatmenton April 12, 2024 at 12:03 am
In a significant stride towards enhancing cancer care in Mangalore and KMC Hospital Attavar Oncology Centre (KMCHAOC) proudly announces the introduction of Stereotactic Radiotherapy, a cutting-edge ...
- 13 Best Penny Stocks to Buy According to Billionaire Ken Griffinon April 8, 2024 at 2:54 pm
In this article, we will take a look at the 13 best penny stocks to buy according to billionaire Ken Griffin. To see more such companies, go directly to 5 Best Penny Stocks to Buy According to ...
via Bing News